Rapid Stabilization of Vulnerable Carotid Plaque Within 1 Month of Pitavastatin Treatment in Patients With Acute Coronary Syndrome

We determined time course of stabilization of echolucent carotid plaques by statin therapy in patients with acute coronary syndrome (ACS). Treatment with 4 mg/d pitavastatin (n = 33) or placebo (n = 32) was initiated within 3 days after onset of ACS in 65 patients with echolucent carotid plaque. Vulnerable carotid plaques were assessed by measuring plaque echolucency using carotid ultrasound with integrated backscatter (IBS) analysis before and 1 month after treatment in all patients. The calibrated IBS value (intima-media IBS value minus adventia IBS) of vulnerable carotid plaques favorably changed at 1 month after treatment in both groups, but the echolucency at 1 month improved more in the pitavastatin than in the placebo group (pitavastatin group: -18.7 ± 3.3 dB at pretreatment versus -12.7 ± 2.3 dB at 1 month *P < 0.001; placebo: -19.0 ± 3.5 dB versus -16.9 ± 3.2 dB, P < 0.05, *P < 0.01 versus the value at 1 month in placebo group). Levels of CRP, VEGF, and TNFα at 1 month were significantly lower in pitavastatin than placebo group. In conclusion, pitavastatin improved carotid plaque echolucency within 1 month of therapy in patients with ACS, in association with decrease in the inflammatory biomarkers related to vulnerable plaques.

[1]  Takamitsu Nakamura,et al.  Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. , 2006, Journal of the American College of Cardiology.

[2]  T. Hirai,et al.  Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. , 2005, Journal of the American College of Cardiology.

[3]  C. Cannon,et al.  The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. , 2005, Journal of the American College of Cardiology.

[4]  E. Braunwald,et al.  Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.

[5]  E. Papalambros,et al.  Changes in circulating levels of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 after carotid endarterectomy. , 2004, International journal of molecular medicine.

[6]  Tomohiro Sakamoto,et al.  Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. , 2004, Journal of the American College of Cardiology.

[7]  K. Vadikolias,et al.  Carotid Plaque Echomorphology and Serum Vascular Endothelial Growth Factor Levels , 2004, European Neurology.

[8]  K. Smith,et al.  Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes. , 2003, Journal of the American College of Cardiology.

[9]  C. Heeschen,et al.  Prognostic Significance of Angiogenic Growth Factor Serum Levels in Patients With Acute Coronary Syndromes , 2003, Circulation.

[10]  U. Schminke,et al.  Volumetric Assessment of Plaque Progression With 3‐Dimensional Ultrasonography Under Statin Therapy , 2002, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[11]  O. Pachinger,et al.  Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. , 2002, Journal of the American College of Cardiology.

[12]  J. Ambrose,et al.  A New Paradigm for Plaque Stabilization , 2002, Circulation.

[13]  A. Nicolaides,et al.  Significance of sonographic tissue and surface characteristics of carotid plaques. , 2001, AJNR. American journal of neuroradiology.

[14]  B. Meier,et al.  Evaluation of the Culprit Plaque and the Physiological Significance of Coronary Atherosclerotic Narrowings , 2001, Circulation.

[15]  Torben V. Schroeder,et al.  Ultrasonic Echolucent Carotid Plaques Predict Future Strokes , 2001, Circulation.

[16]  M. Dake,et al.  Vascular endothelial growth factor enhances atherosclerotic plaque progression , 2001, Nature Medicine.

[17]  P. Shah,et al.  Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.

[18]  T. Ogihara,et al.  Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries. , 2000, Circulation.

[19]  S H Lee,et al.  Early expression of angiogenesis factors in acute myocardial ischemia and infarction. , 2000, The New England journal of medicine.

[20]  C. Warlow,et al.  Evidence of a chronic systemic cause of instability of atherosclerotic plaques , 2000, The Lancet.

[21]  M. Kitahara,et al.  Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. , 1999, Atherosclerosis.

[22]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[23]  J. Egido,et al.  HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. , 1998, Journal of the American College of Cardiology.

[24]  N. Tamura,et al.  Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. , 1998, Circulation.

[25]  W. Brant,et al.  Hypoechoic plaque at US of the carotid artery: an independent risk factor for incident stroke in adults aged 65 years or older. Cardiovascular Health Study. , 1998, Radiology.

[26]  R. Rosenson,et al.  Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.

[27]  B. Buckley,et al.  Statins do more than just lower cholesterol , 1996, The Lancet.

[28]  J. G. Miller,et al.  Quantification of atherosclerotic plaque composition in cholesterol-fed rabbits with 50-MHz acoustic microscopy. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[29]  Steven E. Nissen,et al.  Intravascular Ultrasound Assessment of Lumen Size and Wall Morphology in Normal Subjects and Patients With Coronary Artery Disease , 1991, Circulation.

[30]  Børge G Nordestgaard,et al.  Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. , 2002, Journal of vascular surgery.

[31]  G. Pasterkamp,et al.  Multiple complex coronary plaques in patients with acute myocardial infarction. , 2001, The New England journal of medicine.